Skip to main content
Figure 2 | Diabetology & Metabolic Syndrome

Figure 2

From: Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Figure 2

Once daily injections of liraglutide delay hyperinsulinemia and hyperglycemia in corticosterone-exposed mice. Male C57Bl/6J mice were treated with 1% ethanol (white squares and circles or white bars) or 100 μg/ml corticosterone (black squares and circles or black bars) via the drinking water together with once-daily injections of either PBS (squares or unstriped bars) or liraglutide at a final dose of 0.3 mg per kg body weight (circles or striped bars) for five consecutive weeks (n = 6). Serum insulin levels (A and B) and blood glucose levels (C and D) were determined every week in random-fed animals. Data is shown as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of corticosterone treatment and a # denotes a significant effect of liraglutide.

Back to article page